ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

Bristol Myers Squibb presents data across targeted protein degradation research including CELMoD agents and BCL6 ligand-directed degrader at EHA 2025: Princeton, New Jersey Friday ...

Bristol Myers Squibb has declared a quarterly dividend of $0.62 per share, maintaining its impressive 55-year streak of ...

CHICAGO — In this video, Erica L. Mayer, MD, MPH, discusses the SERENA-6 study, which assessed the efficacy of switching to camizestrant plus a CDK 4/6 inhibitor vs. continuing standard ...

Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and lenvatinib for patients with recurrent or persistent clear-cell ovarian cancer.

Centre for Molecular and Structural Biochemistry, School of Chemistry and School of Biological Sciences, University of East Anglia, Norwich Research Park, NorwichNR4 7TJ, United Kingdom ...

Department of Chemistry, University of Leicester, University Road, Leicester, LE1 7RH, U.K., EaStCHEM, School of Chemistry, University of Edinburgh, West Mains Road ...

This study revealed a significant elevation of circulating CO levels in the morning but not in the evening in OSA patients. The ΔCO, which is the gap between the presleep and postsleep venous CO ...